1477 — Ocumension Therapeutics Share Price
Last trade - 00:00- HK$6.38bn
- HK$5.84bn
- CNY417.31m
- 14
- 14
- 80
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 120.49 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.6 | ||
| Price to Tang. Book | 5.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.74 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.6% | ||
| Return on Equity | -7.76% | ||
| Operating Margin | -45.44% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 13.1 | 56.15 | 158.96 | 246.37 | 417.31 | 826.19 | 1,185.87 | 365.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ocumension Therapeutics is a company primarily engaged in the research, development and commercialization of ophthalmic pharmaceuticals. The products primarily include OT-401 Yutiq fluocinolone intravitreal implant, OT-702 Boyoujing aflibercept intravitreous injection, OT-402 Visudyne, OT- 204 Ou Qin sodium hyaluronate eye drops and OT-305 Betoptic S betaxolol hydrochloride and others. The products are used to treat various anterior and posterior segment eye diseases, such as uveitis, fundus diseases, refractive correction, dry eye disease (DED), glaucoma and conjunctivitis. The Company primarily operates its business in the domestic market.
Directors
- Lian Yong Chen NEC (58)
- Ye Liu CEO (50)
- Changdong Liu CSO (60)
- Zhaopeng Hu EDR (48)
- DongHong Chen OTH (50)
- Qinglei Zuo OTH (37)
- Yun Ji SEC (35)
- Pui Chun Suen SEC (43)
- Yanling Cao NED (37)
- Wei Li NED (49)
- Yumeng Wang NED (30)
- Lianming He NID (56)
- Yiran Huang NID (66)
- Ting Yuk Wu NID (66)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- February 27th, 2018
- Public Since
- July 10th, 2020
- No. of Employees
- 505
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 815,382,414
- Address
- No. 1858 Yinzhongnan Road, SUZHOU, KY1-1205
- Web
- https://www.ocumension.com/
- Phone
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for 1477
Similar to 1477
160 Health International
Stock Exchange of Hong Kong Limited
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
Ab&B Bio Tech Co JS
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 21:25 UTC, shares in Ocumension Therapeutics are trading at HK$7.83. This share price information is delayed by 15 minutes.
Shares in Ocumension Therapeutics last closed at HK$7.83 and the price had moved by +38.34% over the past 365 days. In terms of relative price strength the Ocumension Therapeutics share price has outperformed the FTSE Developed Asia Pacific Index by +15.43% over the past year.
The overall consensus recommendation for Ocumension Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOcumension Therapeutics does not currently pay a dividend.
Ocumension Therapeutics does not currently pay a dividend.
Ocumension Therapeutics does not currently pay a dividend.
To buy shares in Ocumension Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$7.83, shares in Ocumension Therapeutics had a market capitalisation of HK$6.38bn.
Here are the trading details for Ocumension Therapeutics:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1477
Based on an overall assessment of its quality, value and momentum Ocumension Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ocumension Therapeutics is HK$10.53. That is 34.51% above the last closing price of HK$7.83.
Analysts covering Ocumension Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.16 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ocumension Therapeutics. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -6.54%.
As of the last closing price of HK$7.83, shares in Ocumension Therapeutics were trading +2.7% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ocumension Therapeutics PE ratio based on its reported earnings over the past 12 months is 120.49. The shares last closed at HK$7.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ocumension Therapeutics' management team is headed by:
- Lian Yong Chen - NEC
- Ye Liu - CEO
- Changdong Liu - CSO
- Zhaopeng Hu - EDR
- DongHong Chen - OTH
- Qinglei Zuo - OTH
- Yun Ji - SEC
- Pui Chun Suen - SEC
- Yanling Cao - NED
- Wei Li - NED
- Yumeng Wang - NED
- Lianming He - NID
- Yiran Huang - NID
- Ting Yuk Wu - NID